Baumeier C, Aleshcheva G, Harms D, Gross U, Hamm C, Assmus B, Westenfeld R, et al
In 2023, the FDA finalized its reclassification of several peptide compounds including BPC-157, TB-500 (thymosin beta-4), CJC-1295, ipamorelin, and others removing them from the list of bulk drug substances permitted for compounding under Section 503A and 503B of the Food Drug and Cosmetic Act
Mechanism of Action Summary BPC-157 Modulates nitric oxide and VEGF signaling Supports angiogenesis and cytoprotection Influences tendon and ligament matrix signaling TB-500 Influences actin dynamics and cellular migration Supports angiogenesis and re-epithelialization Enhances organized tissue repair processes GHK-Cu Delivers copper for ECM production Stimulates collagen, elastin, and glycosaminoglycans Provides antioxidant and matrix-balancing support Dosing & Clinical Considerations Dosing strategies for peptide blends such as the GLOW Blend Peptide are individualized and depend on clinical goals, route of administration, patient physiology, and the overall treatment plan
Many people think that B12 deficiency can lead to hair loss or alopecia, however, there is little evidence to suggest this is the case
